ES2656712T3 - Novedoso compuesto sustituido con quinolina - Google Patents
Novedoso compuesto sustituido con quinolina Download PDFInfo
- Publication number
- ES2656712T3 ES2656712T3 ES14837210.5T ES14837210T ES2656712T3 ES 2656712 T3 ES2656712 T3 ES 2656712T3 ES 14837210 T ES14837210 T ES 14837210T ES 2656712 T3 ES2656712 T3 ES 2656712T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- group
- amino
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 | ||
| JP2013172746 | 2013-08-22 | ||
| PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656712T3 true ES2656712T3 (es) | 2018-02-28 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14837210.5T Active ES2656712T3 (es) | 2013-08-22 | 2014-08-22 | Novedoso compuesto sustituido con quinolina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (https=) |
| EP (1) | EP3037424B1 (https=) |
| JP (1) | JP6161705B2 (https=) |
| KR (1) | KR101906688B1 (https=) |
| CN (1) | CN105683195B (https=) |
| AU (1) | AU2014309788B2 (https=) |
| BR (1) | BR112016003247B1 (https=) |
| CA (1) | CA2922077C (https=) |
| DK (1) | DK3037424T3 (https=) |
| ES (1) | ES2656712T3 (https=) |
| HU (1) | HUE034807T2 (https=) |
| MX (1) | MX370808B (https=) |
| MY (1) | MY182891A (https=) |
| NO (1) | NO3037424T3 (https=) |
| PH (1) | PH12016500225B1 (https=) |
| PL (1) | PL3037424T3 (https=) |
| PT (1) | PT3037424T (https=) |
| RU (1) | RU2689158C2 (https=) |
| SG (1) | SG11201600759XA (https=) |
| TW (1) | TWI603971B (https=) |
| WO (1) | WO2015025936A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3037424B1 (en) * | 2013-08-22 | 2017-11-08 | Taiho Pharmaceutical Co., Ltd. | Novel quinoline-substituted compound |
| IL266239B2 (en) * | 2016-10-31 | 2023-10-01 | Taiho Pharmaceutical Co Ltd | A selective inhibitor of EGFR with an EXON 20 insertion mutation |
| MA46852A (fr) * | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| HUE066587T2 (hu) * | 2017-09-01 | 2024-08-28 | Taiho Pharmaceutical Co Ltd | Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor |
| IL284330B2 (en) * | 2018-12-28 | 2026-03-01 | Taiho Pharmaceutical Co Ltd | EGFR inhibitor resistant to treatment mutant L718 and/or L792 |
| AU2020240382B2 (en) | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| JP2024523861A (ja) | 2021-06-15 | 2024-07-02 | ジェネンテック， インコーポレイテッド | がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用 |
| CN115707704B (zh) * | 2021-08-20 | 2024-09-13 | 广东医诺维申生物技术有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| JP2025538804A (ja) * | 2022-12-08 | 2025-11-28 | アッシア ケミカル インダストリーズ リミテッド | ジパレルチニブの固体状態の形態及びそれを調製するための方法 |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| EP4722218A1 (en) | 2023-05-31 | 2026-04-08 | Taiho Pharmaceutical Co., Ltd. | Crystal of quinoline-substituted compound |
| WO2025141465A1 (en) | 2023-12-27 | 2025-07-03 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib hydrochloride and process for preparation thereof |
| WO2025167588A1 (zh) * | 2024-02-05 | 2025-08-14 | 苏州科睿思制药有限公司 | Zipalertinib的晶型及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| RU2007138264A (ru) | 2005-03-17 | 2009-09-10 | Новартис АГ (CH) | N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF |
| TWI460177B (zh) | 2009-07-10 | 2014-11-11 | Taiho Pharmaceutical Co Ltd | An azabicyclo compound or a salt thereof |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| BR112013017520A2 (pt) | 2011-01-07 | 2016-09-27 | Taiho Pharmaceutical Co Ltd | composto bicíclico ou sal do mesmo |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| MX351863B (es) * | 2012-02-23 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. |
| EP2960241A4 (en) | 2013-02-22 | 2016-07-13 | Taiho Pharmaceutical Co Ltd | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS AND TRICYCLIC COMPOUNDS MADE ACCORDING TO THE SAID MANUFACTURING METHOD |
| EP3037424B1 (en) * | 2013-08-22 | 2017-11-08 | Taiho Pharmaceutical Co., Ltd. | Novel quinoline-substituted compound |
-
2014
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/en unknown
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active Active
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja not_active Ceased
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225B1/en unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656712T3 (es) | Novedoso compuesto sustituido con quinolina | |
| ES2582315T3 (es) | Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma | |
| ES2942743T3 (es) | Tetrahidropiranil-amino-pirrolopirimidinona para usar en el tratamiento de trastornos mediados por BTK | |
| US10323037B2 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| ES2955132T3 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos | |
| TW202334137A (zh) | Ｐｉ３ｋ抑制劑及治療癌症之方法 | |
| ES2905981T3 (es) | Compuestos y composiciones como inhibidores de los receptores de tipo Toll endosomales | |
| ES2724929T3 (es) | Fármaco antitumoral para la administración intermitente de un inhibidor de FGFR | |
| ES2621220T3 (es) | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas | |
| ES2779225T3 (es) | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos | |
| US20220227738A1 (en) | Kras g12c inhibitors and uses thereof | |
| ES2763274T3 (es) | Carboxamidas de tienopirazina como inhibidores de la proteasa específica de la ubiquitina | |
| BR112014018165B1 (pt) | compostos de indolizina, seu processo de preparação, composições farmacêuticas, seus usos e sal de cloridrato | |
| ES2899694T3 (es) | Compuestos novedosos, su síntesis y sus usos | |
| ES2751642T3 (es) | Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer | |
| JP2018525394A (ja) | Ｉｒａｋ４阻害剤、及びその応用 | |
| ES3035460T3 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| TW202345836A (zh) | 可用作ＮＬＲＰ３衍生物之吡啶并－〔３，４－ｄ〕噠嗪胺衍生物 | |
| US20250059183A1 (en) | Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist | |
| US20240294550A1 (en) | 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof | |
| BR112021000101A2 (pt) | Derivados de tirosina amida como inibidores da rho-quinase, composição farmacêutica, dispositivo, combinação e uso | |
| WO2022127755A1 (en) | Compounds as casein kinase inhibitors | |
| WO2012007619A1 (es) | Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales | |
| CA2909578C (en) | Furanone compounds as kinase inhibitors | |
| JP2024504328A (ja) | 肺疾患の治療のための肺胞２型細胞増殖の小分子調節因子 |